About Us

Our Team: Committed to moving the field of microbiome therapeutics forward

Founder & Chief Executive Officer

Dr. Trebley is Co-founder and CEO of Scioto Biosciences and Monon Bioventures.

Founder and Chief Financial Officer

Mr. Schulz is a serial entrepreneur with over 20 years of financial experience working with public accounting firms, Fortune 500 companies and small start-up companies.

Mark Heiman, Ph.D

Chief Science Officer

Mark L. Heiman, Ph.D. has 20+ years at Eli Lilly & Co where he served as researcher and CSO of obesity drug discovery.

Kevin Meyer

Chief Operating Officer

Kevin Meyer has over 10 years of experience in the life sciences industry, having invented, patented, and commercialized a diverse portfolio of technologies.

Gail E. Besner, M.D.

As a surgeon and scientist, Gail E. Besner, M.D., joined Nationwide Children’s Hospital and The Ohio State University in 1991 upon completion of her pediatric surgical training.

Steve Goodman, Ph.D

Scientific Founder

Since 2012, Dr. Goodman has been the principal investigator in the Center for Microbial Pathogenesis.

Michael Bailey, Ph.D.

Scientific Founder

Studies in Dr. Bailey's laboratory focus on determining the impact that the intestinal microbiota have on the local mucosal immune system, and on immune reactivity at systemic sites, particularly during periods of psychological stress.

Lauren Bakaletz, Ph.D.

Scientific Founder

Lauren O. Bakaletz, Ph.D. is a Professor of both Pediatrics and Otolaryngology and serves as Director of the Center for Microbial Pathogenesis at The Research Institute at Nationwide Children’s Hospital in Columbus, OH.

Revolutionizing Therapeutic Interventions

By enabling beneficial bacteria colonization in the gut, we believe our novel Activated Bacterial Therapeutic (ABT) delivery platform technology will revolutionize therapeutic interventions for diseases where there is erosion of the mucosal barrier.

Erosion of the physical mucus barrier leads to breaches and penetration of toxins, proteins and microbiota to enterocytes of the intestine. The result is collectively termed “leaky gut” and is often associated with low levels of chronic GI and systemic inflammation.

Enabling the delivery of active, live therapeutic bacteria capable of persisting in the gut and primed for adhesion to intestinal mucosa using our ABT technology will serve several unmet medical needs when applied as an intervention to fortify the mucosal barrier in states where breaches are documented.